-- Phase 1a data update from clinical ACTengine(R) programs demonstrated 
      first anti-tumor activity at early phases of dose escalation in heavily 
      pre-treated solid cancer patients 
 
 
   -- Enrollment across clinical ACTengine(R) IMA200 trial series continues to 
      scale up 
 
 
   -- Cash and cash equivalents as well as other financial assets of $285 
      million1 (EUR232 million) as of December 31, 2020 provide cash reach into 
      2023 
 
 
   Tuebingen, Germany and Houston, TX, March 30, 2021 -- Immatics N.V. 
(NASDAQ: IMTX; "Immatics"), a clinical-stage biopharmaceutical company 
active in the discovery and development of T cell redirecting cancer 
immunotherapies, today provided an update on its corporate progress and 
reported financial results for the quarter and full year ended December 
31, 2020. 
 
   Harpreet Singh, Ph.D., CEO of Immatics commented, "The past year was 
exceptional for Immatics with the advancement of our pipeline programs, 
expansion of our leadership team and scientific advisory board and the 
completion of our listing on the Nasdaq. Building on this foundation, we 
have recently delivered encouraging data from three clinical TCR-T 
studies demonstrating first anti-tumor activity in heavily pre-treated 
solid cancer patients. This early data also constitutes a first clinical 
validation for our differentiated TCR therapeutics platform. We look 
forward to reporting further data from our Phase 1 ACTengine(R) TCR-T 
trials as well as the progress in our TCR Bispecifics programs (TCER(R) 
) in the latter part of this year." 
 
   Fourth Quarter 2020 and Subsequent Company Progress 
 
   https://www.globenewswire.com/Tracker?data=m6S2Ug0aJm8JIrkYjqRrJGLe7i9WrJuJEyPFeKfHVQnn877kxoj2I81m6MDcSv8LRSwGJNAMOyHPJB9LfMwUfjqrgBffBKvuru0GGYczGgUpJws5UZB3YsOSovQg72VlHYtGKyNigID3hQ5KhGXIKQ== 
Adoptive Cell Therapy Programs 
 
 
   -- ACTengine(R) IMA200 series - Immatics provided a clinical data update 
      https://investors.immatics.com/news-releases/news-release-details/immatics-presents-data-update-dose-escalation-ongoing-actenginer 
      from three ongoing ACTengine(R) Phase 1 trials for its engineered 
      Adoptive Cell Therapy approach (also known as TCR-T) in March. The 
      combined data readout during early phases of dose escalation for the 
      ACTengine(R) programs, IMA201, IMA202 and IMA203, indicated first 
      anti-tumor activity with tumor shrinkage observed in 8 out of 10 patients 
      including one unconfirmed partial response as of data cut-off. This was 
      consistent with the observed robust engraftment, persistence and tumor 
      infiltration of infused ACTengine(R) T cells. Overall, all product 
      candidates demonstrated a manageable safety and tolerability profile. An 
      additional Phase 1a read-out for IMA201 and IMA203 and initial Phase 1b 
      data for IMA202 from the dose expansion cohort is planned for H2 2021. 
      Submission of a clinical trial application (CTA) for the fourth IMA200 
      series program, IMA204, remains anticipated for H2 2021. The company 
      presented the first preclinical data for the program in September 2020, 
      which is directed at a novel target, COL6A3 exon 6 that is expressed in 
      the tumor stroma of a variety of solid cancers. 
 
 
 
   https://www.globenewswire.com/Tracker?data=kBXmhVA6czQ2wtSmp5GDq1ZkRmuwMjubsDARwwHcSkkPql8yMPHXIUC8J791HLd7W8I1kgq5Emsjj9t79UyEKw9KmwjmjldiIDNyAljaeQXLdB7RVO4eigr9vd_DPIHA 
TCR Bispecifics Programs 
 
 
   -- IMA401 -- Immatics presented 
      https://investors.immatics.com/news-releases/news-release-details/immatics-presents-preclinical-proof-concept-data-tcr-bispecifics 
      preclinical proof-of-concept data from its lead TCER(R) program, IMA401, 
      at the European Antibody Congress 2020 in November. IMA401 is an 
      antibody-like, "off-the-shelf" biologic directed against a high-density 
      peptide target derived from MAGEA4/8. Submission of a CTA for IMA401 
      remains on track by the end of 2021. 
 
   -- IMA402 -- Immatics plans to announce preclinical proof-of-concept data 
      for its second TCER(R) program, IMA402 in Q2 2021. GMP process 
      development activities are targeted to begin at the same time to advance 
      this program towards the Investigational New Drug (IND) stage and 
      clinical development. 
 
 
   Corporate Developments 
 
   Scientific Advisory Board Update 
 
 
   -- Immatics has established a new Scientific Advisory Board (SAB) comprised 
      of several leaders and scientific pioneers in immuno-oncology, adoptive 
      cell therapies, clinical oncology and cancer biology. The members of the 
      new SAB include Gwendolyn Binder, Dirk Busch, Christoph Huber, Patrick 
      Hwu, Roland Kontermann, Crystal Mackall, Hidde Ploegh, Hans-Georg 
      Rammensee, and Cassian Yee. Patrick Hwu and Crystal Mackall will co-chair 
      the SAB. Additional information about the members can be found on the 
      Immatics website https://immatics.com/inside-immatics/sab/ . 
 
 
 
 
   Amendment to Resale Registration Statement 
 
 
   -- In connection with the filing of the Annual Report on Form 20-F, Immatics 
      will file an amendment to its existing resale registration statement on 
      Form F-1 to update certain information. This registration statement 
      relates solely to the resale of shares by certain stockholders, and the 
      filing of the amendment is not necessarily indicative of any sales by the 
      holders of their shares. No shares will be issued or sold by Immatics 
      pursuant to the registration statement. 
 
 
   Full Year 2020 Financial Results 
 
   Cash Position: Cash and cash equivalents as well as other financial 
assets total EUR232.0 million ($284.7 million(1) ) as of December 31, 
2020 compared to EUR119.4 million ($146.5 million(1) ) as of December 
31, 2019. The increase is mainly the result of the business combination 
with ARYA Sciences Acquisition Corporation completed in July 2020 (ARYA 
merger) and the concurrent PIPE Financing. 
 
 
 
   Revenue: Total revenue, consisting of revenue from collaboration 
agreements, was EUR31.3 million ($38.4 million(1) ) for the year ended 
December 31, 2020, compared to EUR18.4 million ($22.6 million(1) ) for 
the year ended December 31, 2019. 
 
   Research and Development Expenses: R&D expenses were EUR67.1 million 
($82.3 million(1) ) for the year ended December 31, 2020, compared to 
EUR40.1 million ($49.2 million(1) ) for the year ended December 31, 
2019. The increase is mainly due to an increase in preclinical and 
clinical development expenses and an increase in share-based 
compensation (EUR14.5 million; $17.8 million(1) for the year ended 
December 31, 2020 compared to EUR1.6 million; $1.9 million for the year 
ended December 31, 2019). 
 
 
 
   General and Administrative Expenses: G&A expenses were EUR34.2 million 
($42.0 million(1) ) for the year ended December 31, 2020, compared to 
EUR11.8 million ($14.5 million(1) ) for the year ended December 31, 
2019. The increase is mainly due to an increase in share-based 
compensation (EUR10.9 million; $13.4 million(1) for the year ended 
December 31, 2020 compared to EUR0.5 million; $0.6 million for the year 
ended December 31, 2019) as well as one-time transaction costs of the 
NASDAQ listing in connection with the ARYA merger in July. 
 
 
 
   Net Loss: Net loss was EUR229.6 million ($281.7 million(1) ) for the 
year ended December 31, 2020, compared to EUR32.5 million ($39.9 
million(1) ) for the year ended December 31, 2019, of which EUR152.8 
million ($187.5 million(1) ) resulted from a one-time, non-cash expense 
in connection with the ARYA merger. The main part of this EUR152.8 
million ($187.5 million(1) ) non-cash expense resulted from the share 
price increase between signing and closing of the ARYA merger. 
 
   Full financial statements can be found in the Annual Report on Form 20-F 
filed with the Securities and Exchange Commission (SEC) and published on 
the SEC website under 
https://www.globenewswire.com/Tracker?data=WFZnFBayeX7hgZ3WW4sRc4-0ngHzvM2f-QFbbElbn_lKY-6KPl1gY7cuFv9q1i9uqELv8VPd80WxC6GYcl8DxA== 
www.sec.gov. 
 
   (1) All amounts translated using the exchange rate published by the 
European Central Bank in effect as of December 31, 2020 (1 EUR = 1.2271 
USD). 
 
   Upcoming Investor Conferences 
 
 
   -- Kempen Life Science -- April 28, 2021 
 
   -- Bank of America Healthcare Conference -- May 11-13, 2021 
 
   -- Jefferies Virtual Healthcare Conference -- June 1-3, 2021 
 
 
 
   To see the full list of events and presentations, visit 
https://www.globenewswire.com/Tracker?data=WFZnFBayeX7hgZ3WW4sRc-Gr4SGKdBlxWgnyORavpiq4nSL9bDHFckJ-6gRftyQgQh06jTJAAsHfDKnOG4SL0Cbh3qdpfCx2GGK_Z5odHLExcEcazY2pJ_iIcsGNX-51RM1hCrCrjLyuQucZIyabka6lC0IuUUuFkrtHbQDRE5k= 
www.investors.immatics.com/events-presentations. 
 
   About Immatics 
 
   Immatics combines the discovery of true targets for cancer 
immunotherapies with the development of the right T cell receptors with 
the goal of enabling a robust and specific T cell response against these 
targets. This deep know-how is the foundation for our pipeline of 
Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships 
with global leaders in the pharmaceutical industry. We are committed to 
delivering the power of T cells and to unlocking new avenues for 
patients in their fight against cancer. 
 
   Immatics intends to use its website 
https://www.globenewswire.com/Tracker?data=WFZnFBayeX7hgZ3WW4sRcw8CnfY9bg6K2pfguz9RsPd7CKDBGyphnDp_VcH9kt576ABWSXpjiY0uweeA9TQqyg== 
www.immatics.com as a means of disclosing material non-public 
information. For regular updates you can also follow us on 
https://www.globenewswire.com/Tracker?data=w8iE04kPEornXSCus2Whrni27lQ6lgFdbIPqcC0DpvjSsa6qC3WNh5uvsu7JV2dSbGs0nUYjbu7fX6vMW8JMiA== 
Twitter and 
https://www.globenewswire.com/Tracker?data=3Otb2xJYScMu2iNhEFMex0PhWQ3q8kBnwZx7uETB-CC_vo9jUJhDSSMcWZhammprqomc_eWWUtMHR5gFBkXtJxkdRN1MGWldRLZUH9yfxssgdVAwWckDU3bnlLF7XPcu 
LinkedIn. 
 
   Forward-Looking Statements

(MORE TO FOLLOW) Dow Jones Newswires

March 30, 2021 07:00 ET (11:00 GMT)